Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | FPR3 | P25089 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844129 | 0.94 | KDR (0.52) | KDRMKNK1CNR1CCNE1CDK2 | |
| Trifluoroacetic Acid SCHEMBL29908119 | 0.82 | USP30 (0.49) | KDRMKNK1CCNE1CDK2CDK5 | |
| SCHEMBL7115045 | 0.82 | USP30 (0.49) | KDRMKNK1CNR1CCNE1CDK2 | |
| SCHEMBL6844027 | 0.80 | MKNK1 (0.54) | KDRMKNK1CNR1CCNE1CDK2 | |
| Trifluoroacetic Acid SCHEMBL7202867 | 0.76 | MKNK1 (0.46) | KDRMKNK1CNR1CCNE1CDK2 | |
| Trifluoroacetic Acid SCHEMBL5354359 | 0.73 | CNR2 (0.56) | KDRMKNK1CCNE1CDK2CDK5 | |
| SCHEMBL2554560 | 0.73 | MKNK1 (0.58) | KDRMKNK1CCNE1CDK2CDK5 | |
| Trifluoroacetic Acid SCHEMBL5354422 | 0.72 | CNR2 (0.55) | KDRMKNK1CNR1CCNE1CDK2 | |
| SCHEMBL19296044 | 0.72 | MKNK1 (0.64) | KDRMKNK1CNR1CCNE1CDK2 | |
| SCHEMBL5353923 | 0.71 | CNR2 (0.59) | KDRMKNK1CCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242637-A1 | Tyrosine kinase inhibitors | HARTMAN GEORGE D (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2003015717-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242637-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885MKNK1 82/4885CNR1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.